The COVID-19 pandemic will negatively impact the European biosurgical agent market in the short term. Once the market stabilizes, the biosurgical agent market in Europe will grow at a modest rate, primarily driven by growing surgical procedure volumes, rising awareness of the benefits of these products in surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, the European market continues to be limited by a lack of reimbursement for biosurgical agents, growing concerns over product cost, and reluctance to use products derived from human tissue among some physicians and patients, hindering the pace of market growth.
This Medtech 360 Report provides high-level market metrics for biosurgical agents in Europe, including country-level data for major countries and aggregate data for the rest of Europe, across a 10-year period.
Table of contents
- Biosurgical Agents - Market Insights - Europe (Supplemental)
Author(s): Nidhi Nagrath
Nidhi Nagrath is an analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at DRG (Part of Clarivate), specializing in the gastrointestinal endoscopy device and diagnostic imaging system servicing markets. Nidhi holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.